Platform
Company
Immunology & Autoimmune
Review status
Currently under review
Pending specialist review and validation.
This test is a screening step that measures how long your blood plasma takes to clot after it is exposed to a special venom reagent that activates part of the clotting pathway. It is called the dilute Russell viper venom time, or dRVVT. The preliminary screen looks for signs of a phospholipid‑dependent inhibitor in your blood, most often a lupus anticoagulant.
In practice, the dRVVT screen is used as part of a broader evaluation for antiphospholipid antibodies. If the screen suggests an inhibitor, additional confirmatory tests and mixing studies are usually performed to clarify the result and rule out other causes.
Doctors order this test when there is suspicion of antiphospholipid syndrome, unexplained blood clots, certain pregnancy complications, or a prolonged clotting time on other routine tests. Finding a lupus anticoagulant can help explain past events and guide decisions about prevention and treatment of future clotting problems.
The dRVVT screen is only one piece of the puzzle. Results are interpreted together with your history, exam, and other blood tests, such as anticardiolipin and anti‑beta‑2 glycoprotein I antibodies. Because several medications and health conditions can affect the result, careful timing and follow‑up testing may be needed to reach a confident diagnosis and to plan safe care.
A prolonged screening result suggests there may be a phospholipid‑dependent inhibitor, but this does not by itself confirm a diagnosis. Your clinician may order confirmatory steps that add excess phospholipid, along with mixing studies, to determine whether the finding is due to an inhibitor or to a factor deficiency. Results can also be influenced by anticoagulant drugs, so testing may be postponed or repeated when medication effects are minimized.
If your result is borderline or unexpected, your care team might repeat the test after some time, or after changes in medication, and pair it with related tests. Your doctor will explain what the pattern of results means for you, whether any treatment changes are needed, and when it is appropriate to recheck.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Direct oral anticoagulants, heparins, and warfarin can prolong clotting times and mimic or mask a lupus anticoagulant. Tell your clinician and the lab about all blood thinners so they can time testing or use mitigation steps appropriately.
Incorrect fill of the blue‑top tube, high hematocrit, delays in centrifugation, or hemolysis and lipemia can alter clotting results. Proper collection, rapid processing, and testing of platelet‑poor plasma are important for reliable results.
Recent infection, surgery, or active inflammation can transiently affect coagulation and lupus anticoagulant assays. Your clinician may avoid testing during acute illness or repeat the test later to confirm persistence.
Testing immediately after a thrombosis or while on initial treatment can be misleading. Results may be deferred or repeated once you are clinically stable and medication effects are better controlled.
Pregnancy and estrogen therapy change clotting factor levels and can influence assay performance and interpretation. Your clinician will consider gestational status and may coordinate testing with specialized labs.
The dRVVT screen is interpreted with confirmatory dRVVT, mixing studies, and other phospholipid‑dependent assays. A consistent pattern across tests is more informative than any single result.
References